
SPRUCE BIOSCIENCES, INC. — Investor Relations & Filings
Spruce Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for serious, underserved neurological disorders. The company's mission is to advance targeted, first-in-class treatments to address significant unmet medical needs. Its lead investigational therapy, TA-ERT, is being advanced for conditions such as MPS IIIB (Sanfilippo Syndrome Type B), a rare and progressive neurological disease. Guided by a patient-centric approach, Spruce Biosciences aims to develop transformative therapies that offer meaningful outcomes beyond conventional approaches.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K | 2026-05-26 | English | |
| 8-K - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer) | 2026-05-13 | English | |
| 424B5 - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer) | 2026-04-21 | English | |
| 424B5 - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer) | 2026-04-20 | English | |
| ARS - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer) | 2026-04-09 | English | |
| DEF 14A - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer) | 2026-04-09 | English |
Browse filings by year
7 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 47072046 | 8-K | 2026-05-26 | English | ||
| 45579664 | 8-K - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer) | 2026-05-13 | English | ||
| 34943609 | 424B5 - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer) | 2026-04-21 | English | ||
| 34693721 | 424B5 - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer) | 2026-04-20 | English | ||
| 33939629 | ARS - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer) | 2026-04-09 | English | ||
| 33939247 | DEF 14A - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer) | 2026-04-09 | English | ||
| 33002588 | 8-K - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer) | 2026-03-20 | English | ||
| 31294669 | SCHEDULE 13G Filing | 2026-02-17 | English | ||
| 31294663 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 31294647 | SCHEDULE 13G Filing | 2026-02-17 | English | ||
| 31294682 | SCHEDULE 13G Filing | 2026-02-10 | English | ||
| 32896600 | 8-K - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer) | 2026-02-05 | English | ||
| 31294656 | 4 Filing | 2026-01-21 | English | ||
| 12983899 | 8-K | 2026-01-08 | English | ||
| 12983900 | Director's Dealing 2026 | 2026-01-05 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
AIM ImmunoTech Inc.
Immuno-pharma company developing therapeutics for oncology,…
|
AIM | US | Professional, scientific and te… |
|
Ainos, Inc.
Develops AI-driven diagnostics, immune therapeutics, and te…
|
AIMD | US | Professional, scientific and te… |
|
Akela Pharma Inc.
Integrated drug developer focused on pain and inhalation, p…
|
— | CA | Professional, scientific and te… |
|
Akero Therapeutics, Inc.
Clinical-stage company developing treatments for serious me…
|
AKRO | US | Professional, scientific and te… |
|
Aladdin Healthcare Technologies SE
Develops AI-powered tools for drug discovery and diagnostic…
|
NMI | DE | Professional, scientific and te… |
|
Alamar Biosciences, Inc.
Powering precision proteomics for earliest disease detectio…
|
ALMR | US | Professional, scientific and te… |
|
Alaunos Therapeutics, Inc.
Clinical-stage immuno-oncology company developing TCR-T cel…
|
TCRT | US | Professional, scientific and te… |
|
ALGORAE PHARMACEUTICALS LIMITED
Biopharmaceutical firm using AI to develop neurodegenerativ…
|
1AI | AU | Professional, scientific and te… |
|
Aligos Therapeutics, Inc.
A clinical-stage biopharmaceutical company developing thera…
|
ALGS | US | Professional, scientific and te… |
|
Allelix Biopharmaceuticals Inc.
Biopharmaceutical R&D focused on protein-based drugs and ne…
|
ALX | CA | Professional, scientific and te… |
SPRUCE BIOSCIENCES, INC. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/35408/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=35408 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=35408 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=35408 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 35408}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for SPRUCE BIOSCIENCES, INC. (id: 35408)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.